The Integrative Mechanism of Xiaoyaosan Through Liver-Brain Crosstalk in the Treatment of Depression Combined with MASLD
- 1College of Traditional Chinese Medicine
- 2Department of Hepatosplenic and Gastrointestinal Diseases
- 3Department of Endocrinology
Abstract
Yunhang Chu,1 Ming Yang,2 Jiahui Liang,1 Xinri Zhang,1 Yan Leng,2 Qi Meng31College of Traditional Chinese Medicine, Changchun University of Chinese Medicine, Changchun, Jilin, People’s Republic of China; 2Department of Hepatosplenic and Gastrointestinal Diseases, Affiliated Hospital of Changchun University of Chinese Medicine, Changchun, Jilin, People’s Republic of China; 3Department of Endocrinology, The Fourth Affiliated Hospital, Changchun University of Chinese Medicine (Changchun People’s Hospital), Changchun, Jilin, People’s Republic of ChinaCorrespondence: Yan Leng, Email [email protected] Qi Meng, Email [email protected]: Depression and metabolic dysfunction-associated steatotic liver disease (MASLD) frequently co-occur, and their bidirectional pathological interactions complicate clinical management. Liver-brain crosstalk provides a systematic framework for understanding these multi-organ connections. Xiaoyaosan (XYS), a classical formula for soothing the liver and relieving depression, has been investigated for its therapeutic potential in both conditions; however, most available evidence remains preclinical. We systematically reviewed 158 original studies graded by evidence level and synthesized the pharmacological mechanisms of XYS. The available evidence suggests that XYS may restore liver-brain communication through vagal, humoral, and gut microbiota pathways. At the vagal pathway level, XYS has been reported to inhibit aberrant afferent transmission of intestinal pro-inflammatory signals to the central nervous system while concurrently enhancing cholinergic anti-inflammatory efferent output, thereby potentially restoring the afferent-efferent balance of autonomic innervation. At the humoral pathway level, XYS may restore the negative feedback function of the hypothalamic-pituitary-adrenal (HPA) axis, redirect tryptophan metabolic flux away from excessive diversion toward the kynurenine pathway, and alleviate neuroinflammation through upregulation of monoamine neurotransmitters and inhibition of microglial M1 polarization. At the gut microbiota pathway level, XYS may reshape microbial community structure and its metabolic profile, restore the microecological barrier and intestinal mucosal permeability by increasing the abundance of short-chain fatty acid-producing bacteria and reducing enterogenous endotoxin load. Two integrative nodes, namely the serotonergic redirection of tryptophan flux and the systematic restoration of gut microbiota, are proposed to underlie the dual efficacy. These nodes may form a bidirectional closed loop that links peripheral metabolic signals with central neuroplasticity. Current evidence has notable limitations, including poor clinical relevance of disease models, insufficient causal inference, questionable dose extrapolation, and lack of temporal dynamics. Future studies should prioritize randomized controlled trials in comorbid populations, multi-omics biomarker discovery, and temporal causal network analysis to facilitate clinical translation.Keywords: Xiaoyaosan, depression, metabolic dysfunction-associated steatotic liver disease, liver-brain crosstalk, homotherapy for heteropathy
Related
- Modified Xiaoyaosan Regulates the Neuro-Immune Microenvironment in Chronic Stress: A Preclinical Meta-Analysis and NF-kappaB Pathway Mechanism Exploration
- Exercise-related brain remodeling through bidirectional brain-body crosstalk: an integrative narrative review.
- Integrative options for the management of anxiety and depression in people with cancer.
- Research progress on the mechanism of microglia–astrocyte signal crosstalk in central sensitization of vestibular migraine
- Hybrid Explainable Deep Ensemble Framework with self-attention mechanism for early prediction of depression severity using PHQ-9 clinical and behavioral data
BibTeX
@article{chu2026integrative,
title = {{The Integrative Mechanism of Xiaoyaosan Through Liver-Brain Crosstalk in the Treatment of Depression Combined with MASLD}},
author = {Chu Y and Yang M and Liang J and Zhang X and Leng Y and Meng Q},
journal = {Drug Design, Development and Therapy},
year = {2026},
month = nov,
doi = {10.2147/dddt.s650753},
url = {https://www.dovepress.com/the-integrative-mechanism-of-xiaoyaosan-through-liver-brain-crosstalk--peer-reviewed-fulltext-article-DDDT},
note = {CC BY-NC 4.0},
}
RIS
TY - JOUR
TI - The Integrative Mechanism of Xiaoyaosan Through Liver-Brain Crosstalk in the Treatment of Depression Combined with MASLD
AU - Chu Y
AU - Yang M
AU - Liang J
AU - Zhang X
AU - Leng Y
AU - Meng Q
PY - 2026
DA - 2026/11/01
JO - Drug Design, Development and Therapy
DO - 10.2147/dddt.s650753
UR - https://www.dovepress.com/the-integrative-mechanism-of-xiaoyaosan-through-liver-brain-crosstalk--peer-reviewed-fulltext-article-DDDT
AB - Yunhang Chu,1 Ming Yang,2 Jiahui Liang,1 Xinri Zhang,1 Yan Leng,2 Qi Meng31College of Traditional Chinese Medicine, Changchun University of Chinese Medicine, Changchun, Jilin, People’s Republic of China; 2Department of Hepatosplenic and Gastrointestinal Diseases, Affiliated Hospital of Changchun University of Chinese Medicine, Changchun, Jilin, People’s Republic of China; 3Department of Endocrinology, The Fourth Affiliated Hospital, Changchun University of Chinese Medicine (Changchun People’s Hospital), Changchun, Jilin, People’s Republic of ChinaCorrespondence: Yan Leng, Email [email protected] Qi Meng, Email [email protected]: Depression and metabolic dysfunction-associated steatotic liver disease (MASLD) frequently co-occur, and their bidirectional pathological interactions complicate clinical management. Liver-brain crosstalk provides a systematic framework for understanding these multi-organ connections. Xiaoyaosan (XYS), a classical formula for soothing the liver and relieving depression, has been investigated for its therapeutic potential in both conditions; however, most available evidence remains preclinical. We systematically reviewed 158 original studies graded by evidence level and synthesized the pharmacological mechanisms of XYS. The available evidence suggests that XYS may restore liver-brain communication through vagal, humoral, and gut microbiota pathways. At the vagal pathway level, XYS has been reported to inhibit aberrant afferent transmission of intestinal pro-inflammatory signals to the central nervous system while concurrently enhancing cholinergic anti-inflammatory efferent output, thereby potentially restoring the afferent-efferent balance of autonomic innervation. At the humoral pathway level, XYS may restore the negative feedback function of the hypothalamic-pituitary-adrenal (HPA) axis, redirect tryptophan metabolic flux away from excessive diversion toward the kynurenine pathway, and alleviate neuroinflammation through upregulation of monoamine neurotransmitters and inhibition of microglial M1 polarization. At the gut microbiota pathway level, XYS may reshape microbial community structure and its metabolic profile, restore the microecological barrier and intestinal mucosal permeability by increasing the abundance of short-chain fatty acid-producing bacteria and reducing enterogenous endotoxin load. Two integrative nodes, namely the serotonergic redirection of tryptophan flux and the systematic restoration of gut microbiota, are proposed to underlie the dual efficacy. These nodes may form a bidirectional closed loop that links peripheral metabolic signals with central neuroplasticity. Current evidence has notable limitations, including poor clinical relevance of disease models, insufficient causal inference, questionable dose extrapolation, and lack of temporal dynamics. Future studies should prioritize randomized controlled trials in comorbid populations, multi-omics biomarker discovery, and temporal causal network analysis to facilitate clinical translation.Keywords: Xiaoyaosan, depression, metabolic dysfunction-associated steatotic liver disease, liver-brain crosstalk, homotherapy for heteropathy
SN - 1177-8881
ER -